CX-5461 can destabilize replication forks in PARP inhibitor-resistant models of ovarian cancer

Acquired drug resistance leads to poor clinical outcome in high grade serous ovarian cancer (HGSOC). We have demonstrated the efficacy of the novel drug CX-5461 in HGSOC is mediated through destabilization of DNA replication forks. The data highlights the potential of CX-5461 in overcoming a general...

Descripción completa

Detalles Bibliográficos
Autores principales: Xuan, Jiachen, Pearson, Richard B., Sanij, Elaine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Author’s Views
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7671053/
https://www.ncbi.nlm.nih.gov/pubmed/33235908
http://dx.doi.org/10.1080/23723556.2020.1805256

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7671053/
https://www.ncbi.nlm.nih.gov/pubmed/33235908
http://dx.doi.org/10.1080/23723556.2020.1805256

Ejemplares similares